Chase Kwon, MD
Dermatology · Hinsdale, ILNPI 1801384029
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Sanofi at 45.3% of the total. 2025 is the largest year on record at $11,078, 6.2 times the $1,789 reported in 2022.
Across 349 payments — averaging $50.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$8K
- Johnson & Johnson$1K
- Regeneron Healthcare Solutions, Inc.$980
- Incyte Corporation$834
- AbbVie$831
- Galderma Laboratories, L.p.$656
- plus $5K from 26 others
What the payments were for
- Consulting fees$6,59837%
- Travel & lodging$4342%
- Food & beverage$10,21558%
- Education$3982%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 28 | $7,989 |
| Johnson & Johnson | 58 | $1,175 |
| Regeneron Healthcare Solutions, Inc. | 28 | $980 |
| Incyte Corporation | 25 | $834 |
| AbbVie(2 entities) | 48 | $831 |
| Galderma Laboratories, L.p. | 11 | $656 |
| Lilly USA, LLC | 25 | $632 |
| UCB, Inc. | 14 | $621 |
| Dermavant Sciences, Inc. | 17 | $585 |
| Pfizer | 18 | $532 |
| LEO Pharma Inc. | 12 | $530 |
| Sun Pharmaceutical Industries Inc. | 8 | $432 |
| Arcutis Biotherapeutics, Inc. | 13 | $420 |
| Amgen | 9 | $257 |
| E.r. Squibb & Sons, L.L.C. | 4 | $227 |
| Janssen Scientific Affairs, LLC | 2 | $188 |
| Organon | 3 | $165 |
| Novartis | 9 | $156 |
| Revance Therapeutics, Inc. | 1 | $92 |
| Boehringer Ingelheim | 2 | $41 |
| Verrica Pharmaceuticals Inc. | 2 | $39 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 2 | $39 |
| Smith+Nephew | 1 | $31 |
| EPI Health, LLC | 1 | $30 |
| Mayne Pharma Commercial LLC | 1 | $29 |
| Krystal Biotech Inc | 1 | $25 |
| Renalytix AI, Inc. | 1 | $22 |
| Medimetriks Pharmaceuticals, Inc. | 1 | $20 |
| Botanix SB Inc | 1 | $19 |
| Biofrontera Inc. | 1 | $19 |
| Almirall LLC | 1 | $18 |
| Journey Medical Corporation | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,645 in reported general payments places this provider in the 85th percentile of 606 dermatology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 25 | $510,146 |
| Dupixent PenDupilumab | 83 | $306,694 |
| Humira(Cf) PenAdalimumab | 19 | $183,466 |
| OtezlaApremilast | 34 | $164,842 |
| Fluorouracil | 37 | $3,142 |
| Clobetasol Propionate | 68 | $2,934 |
| Tacrolimus | 23 | $2,574 |
| Triamcinolone Acetonide | 167 | $2,191 |
| Fluocinonide | 53 | $1,887 |
| Ketoconazole | 112 | $1,573 |
| Doxycycline Hyclate | 42 | $1,060 |
| Clindamycin Phosphate | 23 | $1,021 |
| Desonide | 23 | $1,018 |
| Fluocinolone Acetonide | 13 | $865 |
| Doxycycline Monohydrate | 15 | $650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $257 | $164,84234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 606 dermatology providers in Illinois.
Other dermatology in Hinsdale
- Alix CharlesHinsdale$47K
- Matthew HarrisHinsdale$31K
- Ahmad AminNaperville$4.1M
- Raj ChovatiyaChicago$3.6M
- George LewittNorthbrook$3M
- Peter LioChicago$2.4M
- Elizabeth KiracofeChicago$1.6M
- Lana SchmidtEffingham$1.3M
- Melissa AbramsVernon Hills$600K
- Carolyn JacobChicago$566K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.